

PRESS RELEASE

Stockholm, Sweden, 3 May 2017



Sobi opens office in Greece

[Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) will today formally open a new office in Athens, Greece. The launch event will start with a ribbon cutting ceremony in Aegli Zappeiou.

“Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients, wherever they are. The opening in Greece supports our efforts in meeting the needs for treatment for rare disease patients all over Europe”, says Hege Hellström, President Sobi EMENAR.

The ceremony attendees will include Paschalis Apostolides, President of the Hellenic Association of Pharmaceutical Companies (SFEE) and Dimitris Verykios, Vice President of the Greek Haemophilia Society as well as Hege Hellström, President Sobi EMENAR, Sergio Lai, General Manager Sobi, Italy, Greece, Cyprus and Malta and Nicola Zancan, Market Development Director Sobi, Greece, Cyprus and Malta.

“Our Athens office will enable expanding access to innovative treatments and we aim through close dialogue and cooperation with the Greek authorities to provide high quality care and sustainable access to treatment for people living with rare diseases in Greece”, says Sergio Lai, General Manager Sobi, Italy, Greece, Cyprus and Malta.

“We would like to welcome Sobi to Greece and as a future member of SFEE. As a leading international company with know-how in biochemistry and biologic therapies, we are assured that Sobi can provide new and innovative therapeutic solutions for the Greek people”, says Paschalis Apostolides, President of SFEE.

“The Greek Hemophilia Society welcomes Sobi to Greece and hopes that its presence in our country will contribute to providing high quality products and sustainable access to therapeutic treatments for people with haemophilia and other inherited bleeding disorders”, says Dimitris Verykios, Vice President of the Greek Haemophilia Society.

About Sobi™

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016 Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact:

Media relations

Linda Holmström, Senior Communications Manager

T: + 46 708 73 40 95, + 46 8 697 31 74

linda.holmstrom@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +1 347 224 0819, +1 212 579 0506, +46 8 697 2135

jorgen.winroth@sobi.com